The first session of the CAP-ACP Virtual Education Series 2023 is open to all! Don't forget to register for full series on CAP-ACP website.
Early in 2020year, Health canada approved Abemaciclib which is a CDK4/6 inhibitor in the adjuvant setting in HR+, HER2 negative, node-positive breast cancer patients at high risk of early recurrence.
The approval was based on the results from monarchE, a phase 3 clinical trial in early-stage chemotherapy-naïve, HR+, HER2 negative, node-positive breast cancer patients at high risk of early recurrence. The study has shown significant improvement in invasive disease-free survival (IDFS) with CDK4/6 inhibitor (Abemaciclib) when combined with adjuvant endocrine therapy at two years with a larger absolute benefit in Ki67 high tumors. Although the monarchE data showed that Ki67 is prognostic and has a limited role as a predictive mark
At the end of the session, participants will be able to:
* Identify the limitations associated with Ki67 testing
* Assess when to test and which tissue type to test
* Identify issues related to analytical validation and which antibody clone to use
* Describe how to read it, what constitutes a positive nucleus, how many cells should be counted
* Identify how to report Ki67
Target audience: Pathologists, Residents, Medical Students
CanMEDS Roles: Medical Expert (the integrating role), Communicator, Collaborator, Leader, Health Advocate, Scholar
Speakers: Dr. Hala Faragalla & Dr. Sharon Nofech Mozes
Declaration of Conflict of Interest: Dr. Faragalla has a relationship with PRECISION RX - DX by answering questions related to Ki67 assay and reporting.
This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the Canadian Association of Pathologists. You may claim a maximum of 1.5 hour (credits are automatically calculated).